Krystal Biotech, Inc. KRYS
345.82
0.86
0.25%
as of 25 Sep
- Market cap
- $10.2B
- P/E
- 41.9×
Follow KRYS
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 20.12% | 19.90% | 18.91% | 19.66% |
+8 more TTM periods Free account |
|
| 18.30% | 18.21% | 17.14% | 17.90% | ||
ROIC |
24.07% | 24.64% | 25.73% | 24.34% | |
Return on Tangible Assets |
22.23% | 21.12% | 19.10% | 20.23% | |
Average Days of Receivables |
114.90 | 111.10 | 119.52 | 126.80 | |
Free Cash Flow per Share |
8.73 | 8.11 | 6.54 | 5.73 | |
Free Cash Flow |
257.78 | 237.38 | 189.35 | 166.02 | |
Capital Expenditures |
(14.56) | (12.89) | (11.52) | (10.18) | |
Piotroski F-Score |
5.00 | 5.00 | 6.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
12.35% | 11.92% | 9.81% | 9.43% | |
Accounts Receivable Turnover |
3.52 | 3.62 | 3.35 | 3.29 | |
Accounts Payable Turnover |
3.46 | 7.20 | 5.61 | 5.58 | |
Inventory Turnover |
0.62 | 0.67 | 0.69 | 0.76 | |
Average Days of Payables |
101.14 | 61.31 | 51.28 | 35.76 | |
Days of Inventory on Hand |
704.10 | 639.41 | 640.96 | 641.70 | |
Tax Rate |
0.07 | 0.09 | 0.08 | 0.06 | |
Research and Development Expense of Revenue |
13.45% | 14.17% | 14.92% | 15.22% | |
Selling, General and Administrative Expense of Revenue |
36.30% | 37.17% | 37.71% | 36.60% | |
Share Based Compensation of Revenue |
12.41% | 13.09% | 14.01% | 14.50% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.13 | 1.11 | 0.98 | 0.89 | |
Depreciation/Fixed assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Capex/Depreciation |
(2.18) | (1.94) | (1.76) | (1.60) | |
Revenue per Share |
14.92 | 14.25 | 13.44 | 12.89 | |
Operating CF per Share |
9.22 | 8.55 | 6.94 | 6.09 | |
Capex per Share |
(0.49) | (0.44) | (0.40) | (0.35) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
54.82% | 53.92% | 52.64% | 53.30% |
Columns are period end dates